Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Athenex stock
Learn how to easily invest in Athenex stock.
Athenex Inc is a drug manufacturers-specialty & generic business based in the US. Athenex shares (ATNX) are listed on the NASDAQ and all prices are listed in US Dollars. Athenex employs 652 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Athenex
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ATNX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Athenex stock price (NASDAQ: ATNX)Use our graph to track the performance of ATNX stocks over time.
Athenex shares at a glance
|Latest market close||$0.49|
|52-week range||$0.41 - $4.53|
|50-day moving average||$0.51|
|200-day moving average||$1.36|
|Wall St. target price||$2.75|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.78|
Buy Athenex shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Athenex stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Athenex price performance over time
|1 week (2022-06-30)||19.07%|
|1 month (2022-06-03)||-1.34%|
|3 months (2022-04-07)||-41.40%|
|6 months (2022-01-06)||-63.11%|
|1 year (2021-07-07)||-87.92%|
|2 years (2020-07-07)||-96.34%|
|3 years (2019-07-05)||19.6|
|5 years (2017-07-07)||18.42|
|Revenue TTM||$108.9 million|
|Gross profit TTM||$37.8 million|
|Return on assets TTM||-25.19%|
|Return on equity TTM||-244.69%|
|Market capitalisation||$45.8 million|
TTM: trailing 12 months
Athenex share dividends
We're not expecting Athenex to pay a dividend over the next 12 months.
Athenex share price volatility
Over the last 12 months, Athenex's shares have ranged in value from as little as $0.405 up to $4.525. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athenex's is 0.9657. This would suggest that Athenex's shares are less volatile than average (for this exchange).
Athenex, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors.
Athenex in the news
Athenex shows difficulty of drug development. Should Buffalo keep trying?
Athenex 參與 Truist Securities 細胞治療座談會
Athenex to Participate in Truist Securities Cell Therapy Symposium
Frequently asked questionsWhat percentage of Athenex is owned by insiders or institutions?
Currently 13.147% of Athenex shares are held by insiders and 46.064% by institutions. How many people work for Athenex?
Latest data suggests 652 work at Athenex. When does the fiscal year end for Athenex?
Athenex's fiscal year ends in December. Where is Athenex based?
Athenex's address is: Conventus Building, Buffalo, NY, United States, 14203 What is Athenex's ISIN number?
Athenex's international securities identification number is: US04685N1037 What is Athenex's CUSIP number?
Athenex's Committee on Uniform Securities Identification Procedures number is: 04685N103
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert